2016 American Transplant Congress
Examining the Risk for Post-Transplant Viral Infections and Lymphoproliferative Disorder (PTLD) in Kidney Transplant Patients (Pts) Receiving Calcineurin Inhibitor-Based Immunosuppression (CNI-IS) Compared to Belatacept (CTLA4Ig).
Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA.
Introduction: CTLA4Ig is a novel IS agent that acts through costimulatory blockade of T-cells and obviates the need for CNI. Despite benefits in improving renal…2016 American Transplant Congress
Belatacept Immunotherapy Is Not Augmented by Blockade of Activated LFA-1 in a Nonhuman Primate Renal Transplant Model.
1Department of Surgery, Duke University Medical Center, Durham, NC; 2Emory University, Atlanta, GA.
Purpose: Belatacept specifically targets de novo alloimmune responses without off target side effects. However, resistant alloreactive memory T cells have complicated its use. LFA-1 therapy…2016 American Transplant Congress
Tracking of Endogenous Graft-Reactive Tregs Reveals Their Peripheral Enrichment During Transplantation Tolerance.
Purpose: Our goal for this study was to determine the relative fates of endogenous Foxp3- conventional (Tconv) and Foxp3+ regulatory T cells (Tregs) specific for…2016 American Transplant Congress
The BEST Trial: A Prospective Randomized Trial of Belatacept-Based, CNI- and Corticosteroid-Free Immunosuppression.
Efficacy of CNI- and corticosteroid-free immunosuppressive regimens has not been demonstrated in large, multicenter trials. BEST (Belatacept-based Early Steroid Withdrawal Trial) (NCT 01729494) compares 2…2016 American Transplant Congress
Role of Regulatory T Cells in Induction of Tolerance in Mouse Vascularized Osteomyocutaneous Allotransplantation Under Combined Costimulation Blockade.
Background: The role of regulatory T cells (Tregs) in allograft tolerance has been studied using various transplant models, but the mechanism in vascularized composite allotransplantation…2016 American Transplant Congress
Patients Treated with Belatacept Show Low Levels of APRIL and HLA Antibodies.
Belatacept, a fusión protein that blocks the B7-CD28 costimulation pathway, decreases the level of antibodies in non-human primates and murine models but, few studies have…2016 American Transplant Congress
CD4 T Cell Mediated Help Is Required for Intra-Allograft Proliferation of Endogenous Memory CD8 T Cells and Their Ability to Mediate Rejection of Cardiac Allografts Subjected to Prolonged Ischemia.
Immunology, Cleveland Clinic, Cleveland, OH.
Memory T cells are critical components to protective immunity against recurrent pathogens, but memory T cells with donor-reactivity pose a major barrier to successful transplantation…2016 American Transplant Congress
Evaluating Posttransplant BKV-Specific T Cell Responses in Patients with Alemtuzumab Induction and Belatacept-Based Regimen.
Department of Surgery, Duke University, Durham, NC.
Belatacept-based maintenance regimens prevent acute allograft rejection following alemtuzumab induction, and patients so treated maintain intact anti-CMV and -EBV T cell immune responses without viral…2016 American Transplant Congress
Combined CD122 and Costimulation Blockade Prolongs Allograft Survival by Controlling Expansion and Effector Function of Memory CD8 T Cells.
1Emory Transplant Center, Emory University, Atlanta, GA; 2JN Biosciences, Mountain View, CA.
CD8 memory T cells rely on signaling through CD122, the shared IL-2 and IL-15 receptor β-chain. The addition of anti-CD122 to costimulation blockade prolongs graft…2016 American Transplant Congress
Investigating Posttransplant Allo-Donor Specific CD57+ Cells in Patients with Alemtuzumab Induction and Belatacept-Based Regimen.
Department of Surgery, Duke University, Durham, NC.
Recent studies have showed correlation between CD4+CD57+PD1- cells and costimulation blockade resistant rejection (CoBRR) in patients treated with belatacept without depletional induction. We have recently…
- « Previous Page
- 1
- …
- 20
- 21
- 22
- 23
- 24
- …
- 30
- Next Page »